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Summary 
These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the use 
of a quadrivalent human papillomavirus (HPV) vaccine licensed by the U.S. Food and Drug Administration on June 8, 2006. 
This report summarizes the epidemiology of HPV and associated diseases, describes the licensed HPV vaccine, and provides 
recommendations for its use for vaccination among females aged 9–26 years in the United States. 
Genital HPV is the most common sexually transmitted infection in the United States; an estimated 6.2 million persons are 
newly infected every year. Although the majority of infections cause no clinical symptoms and are self-limited, persistent infection 
with oncogenic types can cause cervical cancer in women. HPV infection also is the cause of genital warts and is associated with 
other anogenital cancers. Cervical cancer rates have decreased in the United States because of widespread use of Papanicolaou 
testing, which can detect precancerous lesions of the cervix before they develop into cancer; nevertheless, during 2007, an esti­
mated 11,100 new cases will be diagnosed and approximately 3,700 women will die from cervical cancer. In certain countries 
where cervical cancer screening is not routine, cervical cancer is a common cancer in women. 
The licensed HPV vaccine is composed of the HPV L1 protein, the major capsid protein of HPV.  Expression of the L1 protein 
in yeast using recombinant DNA technology produces noninfectious virus-like particles (VLP) that resemble HPV virions. The 
quadrivalent HPV vaccine is a mixture of four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18 
combined with an aluminum adjuvant. Clinical trials indicate that the vaccine has high efficacy in preventing persistent HPV 
infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 
6, 11, 16, or 18 among females who have not already been infected with the respective HPV type. No evidence exists of protection 
against disease caused by HPV types with which females are infected at the time of vaccination. However, females infected with 
one or more vaccine HPV types before vaccination would be protected against disease caused by the other vaccine HPV types. 
The vaccine is administered by intramuscular injection, and the recommended schedule is a 3-dose series with the second and 
third doses administered 2 and 6 months after the first dose. The recommended age for vaccination of females is 11–12 years. 
Vaccine can be administered as young as age 9 years. Catch-up vaccination is recommended for females aged 13–26 years who 
have not been previously vaccinated. Vaccination is not a substitute for routine cervical cancer screening, and vaccinated females 
should have cervical cancer screening as recommended. 
Introduction	 and are self-limited, persistent genital HPV infection can cause 
cervical cancer in women and other types of anogenital can-
Genital human papillomavirus (HPV) is the most com­
cers and genital warts in both men and women.
mon sexually transmitted infection in the United States; an 
Approximately 100 HPV types have been identified, over 
estimated 6.2 million persons are newly infected every year 
40 of which infect the genital area (2). Genital HPV types are
(1). Although the majority of infections cause no symptoms 
categorized according to their epidemiologic association with 
cervical cancer. Infections with low-risk types (e.g., types 6 
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abnormalities, high-grade cervical cell abnormalities that are 
precursors to cancer, and anogenital cancers (5). High-risk 
HPV types are detected in 99% of cervical cancers (6); 
approximately 70% of cervical cancers worldwide are caused 
by types 16 and 18 (7). Although infection with high-risk 
types is considered necessary for the development of cervical 
cancer, it is not sufficient because the majority of women with 
high-risk HPV infection do not develop cancer (3,4). 
In addition to cervical cancer, HPV infection also is associ­
ated with anogenital cancers such as cancer of the vulva, vagina, 
penis, and anus (Table 1) (8,9). Each of these is less common 
than cervical cancer (10–14). The association of genital types 
of HPV with nongenital cancer is less well established, but 
studies support a role in a subset of oral cavity and pharyn­
geal cancers (15).
 In June 2006, the quadrivalent HPV vaccine types 
6,11,16,18 (GARDASILTM, manufactured by Merck and Co., 
Inc., Whitehouse Station, New Jersey) was licensed for use 
among females aged 9–26 years* for prevention of vaccine 
HPV-type–related cervical cancer, cervical cancer precursors, 
vaginal and vulvar cancer precursors, and anogenital warts. 
Efficacy studies are ongoing in men.
 In the United States, cervical cancer prevention and con­
trol programs have reduced the number of cervical cancer 
cases and deaths through cervical cytology screening, which 
can detect precancerous lesions. The quadrivalent HPV vac­
cine will not eliminate the need for cervical cancer screening 
in the United States because not all HPV types that cause 
cervical cancer are included in the vaccine. 
* The en dash in numeric ranges is used to represent inclusive years, hours, 
days, ages, dosages, or a sequence of numbered items. 
TABLE 1. Cancers associated with human papillomavirus 
(HPV) and percentage attributable to oncogenic HPV — 
United States, 2003 
% Attributable to 
Cancer Cases* oncogenic HPV† 
Cervix§ 11,820 100 
Anus¶ 4,187 90 
Vulva¶ 3,507 40 
Vagina¶ 1,070 40 
Penis¶ 1,059 40 
Oral cavity and pharynx¶ 29,627 <12 
* Source: U.S. Cancer Statistics Working Group. United States cancer 
statistics: 2003. Incidence and motality. Atlanta, GA: US Department of 
Health and Human Services, CDC, and the National Cancer Institute; 
2006. Available at http://www.cdc.gov/uscs. 
† Source: Parkin M. The global health burden of infection-associated 
cancers in the year 2002. Int J Cancer 2006;118:3030–44. 
§ A total of 70% attributed are HPV types 16 or 18. 
¶ Majority of these cancers attributable to HPV type 16. 
Methods 
The Advisory Committee on Immunization Practices 
(ACIP) HPV vaccine workgroup first met in February 2004 
to begin reviewing data related to the quadrivalent HPV vac­
cine. The workgroup held monthly teleconferences and meet­
ings three times a year to review published and unpublished 
data from the HPV vaccine clinical trials, including data on 
safety, immunogenicity, and efficacy. Data on epidemiology 
and natural history of HPV, vaccine acceptability, and sexual 
behavior in the United States also were reviewed. Several eco­
nomic and cost effectiveness analyses were considered. Pre­
sentations on these topics were made to ACIP during meetings 
in June 2005, October 2005, and February 2006. Recom­
mendation options were developed and discussed by the ACIP 
HPV vaccine workgroup. When evidence was lacking, the 
recommendations incorporated expert opinion of the 
workgroup members. Options being considered by the 
workgroup were presented to ACIP in February 2006. The 
final recommendations were presented to ACIP at the June 
2006 ACIP meeting. After discussions, minor modifications 
were made and the recommendations were approved at the 
June 2006 meeting. Modifications were made to the ACIP 
statement during the subsequent review process at CDC to 
update and clarify wording in the document. 
The quadrivalent HPV vaccine is a new vaccine; additional 
data will be available in the near future from clinical trials. 
These data and any new information on epidemiology of HPV 
will be reviewed by ACIP as they become available, and rec­
ommendations will be updated as needed. 
Background 
Biology of HPV 
HPVs are nonenveloped, double-stranded DNA viruses in 
the family Papillomaviridae. Isolates of HPV are classified as 
“types,” and numbers are assigned in order of their discovery 
(16). Types are designated on the basis of the nucleotide se­
quence of specific regions of the genome. All HPVs have an 8 
kb circular genome enclosed in a capsid shell composed of 
the major and minor capsid proteins L1 and L2, respectively. 
Purified L1 protein will self-assemble to form empty shells 
that resemble a virus, called virus-like particles (VLPs). In 
addition to the structural genes (L1 and L2), the genome en­
codes several early genes (E1, E2, E4, E5, E6, and E7) that 
enable viral transcription and replication and interact with 
the host genome. Immortalization and transformation func­
tions are associated with the E6 and E7 genes of high-risk 
HPV. E6 and E7 proteins from high-risk types are the pri­
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mary oncoproteins; they manipulate cell cycle regulators, in­
duce chromosomal abnormalities, and block apoptosis (17). 
Papillomaviruses initiate infection in the basal layer of the 
epithelium, and viral genome amplification occurs in differ­
entiating cells using the cellular replication machinery. After 
infection, differentiating epithelial cells that are normally 
nondividing remain in an active cell cycle. This can result in 
a thickened, sometimes exophytic, epithelial lesion. The vi­
rus is released as cells exfoliate from the epithelium. With 
neoplastic progression, the virus might integrate into the host 
chromosomes, and little virion production will occur. 
Immunology of HPV 
HPV infections are largely shielded from the host immune 
response because they are restricted to the epithelium (18). 
Humoral and cellular immune responses have been docu­
mented, but correlates of immunity have not been established. 
Serum antibodies against many different viral products have 
been demonstrated. The best characterized and most type-
specific antibodies are those directed against conformational 
epitopes of the L1 capsid protein assembled as VLPs. Not all 
infected persons have antibodies; in one study, 54%–69% of 
women with incident HPV 16, 6, or 18 infections had anti­
bodies (19). Among newly infected women, the median time 
to seroconversion is approximately 8 months (20,21). 
Laboratory Testing for HPV 
HPV cannot be cultured. Detecting HPV requires identifi­
cation of HPV genetic information (DNA in the majority of 
assay formats). Assays differ considerably in their sensitivity 
and type specificity. The anatomic region sampled and the 
method of specimen collection will impact detection. 
Only the Digene Hybrid Capture® 2 (HC2) High-Risk 
HPV DNA Test is approved by the U.S. Food and Drug Ad­
ministration (FDA) for clinical use. The HC2 High Risk test 
uses liquid nucleic acid hybridization and detects 13 high-
risk types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, and 68). Results are reported as positive or negative and 
are not type-specific. The HC2 High Risk test is approved 
for triage of women with equivocal Papanicolaou (Pap) test 
results (atypical squamous cells of undetermined significance 
[ASC-US]) and in combination with the Pap test for cervical 
cancer screening in women aged >30 years. The test is not 
clinically indicated nor approved for use in men. 
Epidemiology and basic research studies of HPV typically 
use nucleic acid amplification methods that generate type-
specific and, in certain formats, quantitative results. Polymerase 
chain reaction (PCR) assays used most commonly in epide­
miologic studies target genetically conserved regions of the L1 
gene. These consensus assays are designed to amplify HPV, and 
types are then determined by type specific hybridization, re­
striction enzyme digestion, or sequencing. In the trials of 
quadrivalent HPV vaccine, multiplex assays were used that spe­
cifically detect the L1, E6, and E7 gene for each HPV type. 
The most frequently used HPV serologic assays are VLP-
based enzyme immunoassays, designed to detect antibodies 
to the L1 viral protein. The type-specificity of the assay de­
pends on preparation of conformationally intact VLPs in re­
combinant baculovirus or other eukaryotic expression systems 
(22). Serologic assays are available only in research settings. 
Key laboratory reagents are not standardized, and no gold 
standards exist for setting a threshold for a positive result (23). 
In trials of the quadrivalent HPV vaccine, a competitive ra­
dioimmunoassay or a quadriplex competitive immunoassay 
was used, both of which measure neutralizing antibodies in 
serum (24,25). 
Epidemiology of HPV Infection 
Transmission and Risk Factors 
Genital HPV infection is primarily transmitted by genital 
contact, usually through sexual intercourse (2,26). In virtu­
ally all studies of HPV prevalence and incidence, the most 
consistent predictors of infection have been measures of sexual 
activity, most importantly the number of sex partners (life­
time and recent) (27–34). For example, one study indicated 
that 14.3% of women aged 18–25 years with one lifetime sex 
partner, 22.3% with two lifetime sex partners, and 31.5% 
with more than three lifetime partners (33) had HPV infec­
tion. Transmission of HPV through other types of genital 
contact in the absence of penetrative intercourse (i.e., oral-
genital, manual-genital, and genital-genital contact) has been 
described, but is less common than through sexual intercourse 
(26,35,36). Additional risk factors primarily identified for fe­
males include partner sexual behavior (26) and immune sta­
tus (37,38). Genital HPV infection also can be transmitted 
by nonsexual routes, but this is uncommon. Nonsexual routes 
of genital HPV transmission include transmission from a 
mother to a newborn baby (39,40). 
Because HPV is transmitted by sexual activity, understand­
ing the epidemiology of HPV requires data on sexual behav­
ior. The 2002 National Survey of Family Growth (http:// 
www.cdc.gov/nchs/nsfg) indicated that 24% of females in the 
United States were sexually active by age 15 years (41). This 
percentage increased to 40% by age 16 years and to 70% by 
age 18 years. Among sexually active females aged 15–19 years 
and 20–24 years, the median number of lifetime male sex 
partners was 1.4 and 2.8, respectively (42). The 2005 Youth 
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mmwrhtml/SS5505a1.htm) indicated that that 3.7% of female 
students had been sexually active before age 13 years (43). Of 
those sexually active, 5.7% of 9th-grade females and 20.2% of 
12th-grade females had had four or more sex partners. 
Natural History of HPV Infection 
The majority of HPV infections are transient and asymp­
tomatic and cause no clinical problems; 70% of new HPV 
infections clear within 1 year, and approximately 90% clear 
within 2 years (27,44–46). The median duration of new in­
fections is 8 months (27,45). Persistent infection with high-
risk types of HPV is the most important risk factor for cervical 
cancer precursors and invasive cervical cancer (45,47–50). The 
risk for persistence and progression to precancerous lesions 
varies by HPV type, with HPV 16 being more oncogenic 
than other high-risk HPV types (51,52). Factors associated 
with cervical cancer in epidemiologic studies include ciga­
rette smoking, increased parity, increased age, other sexually 
transmitted infections, immune suppression, long-term oral 
contraceptive use, and other host factors (53–55). The time 
between initial HPV infection and development of cervical 
cancer is usually decades. Many aspects of the natural history 
of HPV are poorly understood, including the role and dura­
tion of naturally acquired immunity after HPV infection. 
HPV Prevalence and Incidence in the United 
States 
Overall in the United States, an estimated 6.2 million new 
HPV infections occur every year among persons aged 14–44 
years (1). Of these, 74% occur among those aged 15–24 years. 
Modeling estimates suggest that >80% of sexually active women 
will have acquired genital HPV by age 50 years (56). 
Routine reporting of HPV does not exist in the United 
States. Information on prevalence and incidence has been 
obtained primarily from clinic-based populations, such as 
family planning and sexually transmitted disease or univer­
sity health clinic patients. These evaluations have documented 
prevalence of HPV DNA ranging from 14% to 90% (57). 
Prevalence was highest among sexually active females aged 
<25 years and decreased with increasing age (31,32,58,59). 
Data from a multisite, clinic-based study of sexually active 
women in the United States indicated that prevalence was 
highest among those aged 14–19 years (60). 
Two studies have reported prevalence in representative, 
population-based samples. In a study of sexually active women 
aged 18–25 years, prevalence of any HPV was 26.9% (33). 
Prevalence of types 6 or 11 was 2.2%, and prevalence of types 
16 or 18 was 7.8%. In a study of females aged 14–59 years 
during 2003–2004, the prevalence of any HPV was 26.8% 
(61). Prevalence was highest among women aged 20–24 years 
(44.8%). Overall, prevalence of types 6, 11, 16, and 18 was 
1.3%, 0.1%, 1.5%, and 0.8%, respectively. 
Few data exist on cumulative risk for HPV infection. De­
tection of HPV DNA indicates infection and does not pro­
vide information on women who were infected but cleared 
the HPV. Seroprevalence data can provide a better estimate 
of cumulative risk but will also be an underestimate, because 
not all persons with natural HPV infection have detectable 
antibodies. In a representative sample of women aged 20–29 
years in the United States, HPV 16 seroprevalence was 25% 
(62). Because as few as 60% of those infected with HPV have 
detectable antibodies, the seroprevalence is an underestimate, 
and true exposure to HPV 16 could be as high as 41% among 
women in that age group. Data also are available from the 
quadrivalent HPV vaccine phase III trials, in which both HPV 
PCR assays on cervical specimens and serologic tests were 
performed at enrollment. Participation was restricted to sexu­
ally active women who had no more than four lifetime part­
ners or were planning sexual debut. Among 5,996 North 
American females aged 16–24 years, 92% were sexually ac­
tive, and the median number of lifetime sex partners was two; 
24% had evidence of previous or current infection with HPV 
6,11,16, or 18 on the basis of serology and/or PCR at the time 
of enrollment; four (0.1%) had evidence of infection with all 
four vaccine types (Merck and Co., unpublished data, 2006). 
Studies of incident HPV infection that have evaluated HPV 
DNA detection over time demonstrate that acquisition oc­
curs soon after sexual debut. In a prospective study of college 
women in the United States, the cumulative probability of 
incident infection was 38.9% by 24 months after first sexual 
intercourse. Of all HPV types, HPV 16 acquisition was high­
est (10.4%); 5.6% had acquired HPV 18 (26). 
HPV infection also is common among men (63–67). Among 
heterosexual men in clinic-based studies, prevalence of geni­
tal HPV infection often is >20% and is highly dependent on 
the anatomic sites sampled and method of specimen 
collection (64,66,67). 
Clinical Sequelae of HPV Infection 
Clinical sequelae of HPV infection include cervical cancer 
and cervical cancer precursors, other anogenital cancers and 
their precursor lesions, anogenital warts, and recurrent respi­
ratory papillomatosis. 
Cervical Cancer and Precursor Lesions 
HPV is a necessary but not sufficient cause of all cervical 
cancers. Approximately three fourths of all cervical cancers in 
the United States are squamous cell; the remaining are adeno­
carcinomas. HPV 16 and 18 account for approximately 68% 
of squamous cell cancers and 83% of adenocarcinomas (7). 
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Although HPV infection usually is asymptomatic, cervical 
infection can result in histologic changes that are classified as 
cervical intraepithelial neoplasias (CIN) grades 1, 2, or 3 on 
the basis of increasing degree of abnormality in the cervical 
epithelium or adenocarcinoma in situ (AIS). Spontaneous 
clearance or progression to cancer in the absence of treatment 
varies for CIN 1 and CIN 2, and CIN 3. CIN 1 usually clears 
spontaneously (60% of cases) and rarely progresses to cancer 
(1%); a lower percentage of CIN 2 and 3 spontaneously clears 
(30%–40%), and a higher percentage progresses to cancer if 
not treated (>12%) (68). Cervical cancer screening with the 
Pap test can detect cytologic changes that reflect the underly­
ing tissue changes. However, cytologic abnormalities detected 
by the Pap test can be ambiguous or equivocal. Abnormalities 
include ASC-US, atypical glandular cells, low- and high-grade 
squamous intraepithelial lesions (LSIL and HSIL), and AIS. 
HPV types 16 and 18 are more commonly found in associa­
tion with higher-grade lesions. In one study, the prevalence 
of HPV 16 was 13.3% among ASC-US, 23.6% among LSIL, 
and 60.7% among HSIL Pap tests (69). 
No routine reporting or registry exists for abnormal Pap 
tests or cervical cancer precursor lesions in the United States; 
however, data are available from managed-care organizations 
and administrative data sets (70,71). Each year, approximately 
50 million women undergo Pap testing; approximately 3.5– 
5.0 million of these Pap tests will require some follow-up, 
including 2–3 million ASC-US, 1.25 million LSIL, and 
300,000 HSIL Pap tests (72–74). 
In the United States, cases of cervical cancer are routinely 
reported to cancer registries such as the National Cancer In­
stitute Surveillance, Epidemiology, and End Results program, 
and CDC-administered National Program of Cancer Regis­
tries that cover approximately 96% of the U.S. population in 
2003. Cervical cancer incidence rates have decreased approxi­
mately 75% and death rates approximately 70% since the 
1950s, largely because of the introduction of Pap testing 
(74,75). However, the decrease in incidence is observed pri­
marily in squamous cell carcinomas; the incidence of adeno­
carcinomas has not changed appreciably (76). 
Adenocarcinomas are more difficult to detect because they 
are found in the endocervix; they account for approximately 
20% of cervical cancer cases in the United States (77,78). In 
2003, cervical cancer incidence in the United States was 8.1 
per 100,000 women, with approximately 11,820 new cases 
reported (79). The median age of diagnosis for cervical can­
cer was 47 years. 
Substantial differences exist in the cervical cancer incidence 
and mortality by racial/ethnic group in the United States (78). 
The incidence for black women was approximately 1.5 times 
higher than that for white women (Figure 1). Incidence for 
Hispanic women also was higher than that for white women 
(78). Death rates for black women were twice that for white 
women. Although incidence for Asian women overall is simi­
lar to that for white women (78), certain Asian subgroups, 
especially Vietnamese and Korean women, have higher rates 
of cervical cancer (80). 
Geographic differences exist in incidence and mortality, with 
notably higher incidence and mortality in Southern states 
(Figures 2 and 3) and Appalachia (78,81). Mortality rates are 
FIGURE 1. Cervical cancer (invasive) SEER incidence* and 
















1975 1977 1979 1981 1983 1985 1987	 1989 1991 1993 1995 1997 1999 2001 2003 
Year 
Source: National Cancer Institute. SEER Cancer Statistics Review, 1975– 
2003. Bethesda, MD: National Cancer Institute; 2004. 
* Per 100,000 persons and age-adjusted to the 2000 U.S. standard 
population. 
FIGURE 2. Cervical cancer* incidence† — United States, 2003 
DC 
Data not§ Rates are suppressed 4.4–6.6 6.7–8.9 9.0–11.1 11.2–13.3 
available if <16 cases were 
reported in the 
specific category 
Source: U.S. Cancer Statistics Working Group. United States cancer 
statistics: 2003 Incidence and mortality. Atlanta, GA: US Department of 
Health and Human Services, CDC, and National Cancer Institute; 2006. 
Available at http://www.cdc.gov/uscs. 
* Invasive cancers only. 
†Per 100,000 persons and age-adjusted to the 2000 U.S. standard 
population (19 age groups — Census P25-1130). 
§Data are from selected statewide and metropolitan area cancer registries 
that meet the data quality criteria for all invasive cancer sites combined. 
Incidence covers approximately 96% of the U.S. population. 
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FIGURE 3. Cervical cancer death rates* — United States, 2003† 
DC 
Rates are suppressed 1.3–2.0 2.1–2.7 2.8–3.3 3.4–4.0 
if <16 cases were 
reported in the 
specific category 
Source: U.S. Cancer Statistics Working Group. United States cancer 
statistics: 2003 incidence and mortality. Atlanta, GA: US Department of 
Health and Human Services, CDC, and National Cancer Institute; 2006. 
Available at http://www.cdc.gov/uscs. 
* Per 100,000 persons and age-adjusted to the 2000 U.S. standard 
population (19 age groups — Census P25-1130). 
† Data are from the National Vital Statistics System (NVSS). 
higher among specific groups, including Hispanic women 
living on the Texas-Mexico border; white women in Appala­
chia, rural New York State, and the northern part of the north­
east United States; and among American Indians in the 
Northern Plains and Alaska Native women (82). 
Vaginal and Vulvar Cancer and Precursor 
Lesions 
HPV is associated with vaginal and vulvar cancer and vagi­
nal and vulvar intraepithelial neoplasias; however, unlike cer­
vical cancer, not all vaginal and vulvar cancers are associated 
with HPV. The natural history of vaginal and vulvar neopla­
sia is incompletely understood (83,84). No routine screening 
exists for vaginal or vulvar cancer in the United States. 
The majority of vaginal cancers and vaginal intraepithelial 
neoplasias III (VaIN III) are positive for HPV (85); HPV 16 
is the most common type (86,87). Approximately one third 
of women with VaIN or vaginal cancer had been treated pre­
viously for an anogenital cancer, usually cervical cancer (86). 
Vaginal cancer is rare, and incidence has decreased by 20% 
during the preceding two decades. In the United States in 
2003, a total of 1,070 cases of invasive vaginal cancer (age­
adjusted incidence rate: 0.7 per 100,000 females) and 391 
deaths (death rate: 0.2 per 100,000 females) occurred (79). 
The median age for diagnosis of vaginal cancer was 69 years. 
HPV is associated with approximately half of vulvar squa­
mous cell cancers, the most common type of vulvar cancer. 
HPV-associated vulvar cancer tends to occur in younger 
women and might be preceded by vulvar intraepithelial neo­
plasia (VIN). In a recent study, HPV types 16 or 18 were 
detected in 76% of the VIN 2/3 and 42% of vulvar carci­
noma samples (87). In 2003, a total of 3,507 cases of vulvar 
cancer (age-adjusted incidence rate: 2.2 per 100,000) and 775 
deaths (death rate: 0.4 per 100,000 females) occurred in the 
United States (79). During 1973–2000, the incidence of in 
situ vulvar cancer increased by 400%, and the rate of invasive 
vulvar cancer increased by 20%. Changes in detection or re­
porting of in situ cancers might be responsible for the in­
creased rate of in situ cancers (88). 
Anal Cancer 
HPV is associated with approximately 90% of anal squa­
mous cell cancers. Anal intraepithelial neoplasia (AIN) is rec­
ognized as a precursor of anal cancer, although the natural 
history of these lesions (i.e., rate of progression and regres­
sion) is less clear than for CIN (50). Anal cancer is more com­
mon in women (2,516 new cases in 2003 [rate: 1.6 per 
100,000 women]) than in men (1,671 new cases [rate: 1.3 
per 100,000 men]) (79). During the preceding three decades, 
the incidence of anal cancer in the United States has increased, 
especially among men (89). Women at high risk for anal can­
cer include those with high-grade cervical lesions and cervi­
cal and vulvar cancers. Men who have sex with men and persons 
who have human immunodeficiency virus (HIV) infection also 
are at high risk for anal cancer (90). No national recommenda­
tions exist for cytologic screening to prevent anal cancers. 
Genital Warts 
All anogenital warts (condyloma) are caused by HPV, and 
approximately 90% are associated with HPV types 6 and 11 
(91). The average time to development of new anogenital warts 
after infection with HPV types 6 or 11 is approximately 2–3 
months (92). However, not all persons infected with HPV 
types 6 or 11 acquire genital warts. Anogenital warts can be 
treated, although many warts (20%–30%) regress spontane­
ously. Recurrence of anogenital warts is common (approxi­
mately 30%), whether clearance occurs spontaneously or 
following treatment (93). Anogenital warts are not routinely 
reported in the United States. The prevalence of genital warts 
has been examined using health-care claims data (94). An es­
timated 1% of sexually active adolescents and adults in the 
United States have clinically apparent genital warts (29). 
Recurrent Respiratory Papillomatosis 
Infection with low-risk HPV types, primarily types 6 or 
11, rarely results in recurrent respiratory papillomatosis (RRP), 
a disease that is characterized by recurrent warts or papillo­
 
 
7 Vol. 56 / RR-2 Recommendations and Reports 
mas in the upper respiratory tract, particularly the larynx. 
On the basis of age of onset, RRP is divided into juvenile 
onset (JORRP) and adult onset forms. JORRP, generally de­
fined as onset before age 18 years, is better characterized than 
the adult form. JORRP is believed to result from vertical trans­
mission of HPV from mother to baby during delivery, al­
though the median age of diagnosis is 4 years. A multicenter 
registry of JORRP in the United States that collected data 
during 1999–2003 (95) demonstrated that although the clini­
cal course of JORRP was variable, it is associated with exten­
sive morbidity, requiring a median of 13 lifetime surgeries to 
remove warts and maintain an open airway. Estimates of the 
incidence of JORRP are relatively imprecise but range from 
0.12 to 2.1 cases per 100,000 children aged <18 years in two 
cities in the United States (96). The prevalence, incidence, 
and disease course of the adult form of RRP are less clear. 
Treatment of HPV Infection 
HPV infections are not treated; treatment is directed at the 
HPV-associated lesions. Treatment options for genital warts 
and cervical, vaginal, and vulvar cancer precursors include 
various local approaches that remove the lesion (e.g., cryo­
therapy, electrocautery, laser therapy, and surgical excision). 
Genital warts also are treated with topical pharmacologic 
agents (97). On the basis of limited existing data, available 
therapies for HPV-related lesions might reduce but probably 
do not eliminate infectiousness. 
TABLE 2. Cervical cancer screening guidelines — United States 
Prevention 
HPV Infection 
Condom use might reduce the risk for HPV and HPV-
associated diseases (e.g., genital warts and cervical cancer). A 
limited number of prospective studies have demonstrated a 
protective effect of condoms on acquisition of genital HPV. 
A study among newly sexually active college women demon­
strated a 70% reduction in HPV infection when their part­
ners used condoms consistently and correctly (98). Abstaining 
from sexual activity (i.e., refraining from any genital contact 
with another persons) is the surest way to prevent genital HPV 
infection. For those who choose to be sexually active, a mo­
nogamous relationship with an uninfected partner is the strat­
egy most likely to prevent future genital HPV infections. 
Neither routine surveillance for HPV infection nor part­
ner notification is useful for HPV prevention (97). Genital 
HPV infection is so prevalent that the majority of partners 
of persons found to have HPV infection are infected already; 
no prevention or treatment strategies have been recom­
mended for partners. 
Cervical Cancer Screening 
The majority of cervical cancer cases and deaths can be pre­
vented through detection of pre-cancerous changes in the cervix 
by cytology using the Pap test. Pap test screening includes a con­
ventional Pap or a liquid-based cytology (99). CDC does not 
issue recommendations for cervical cancer screening, but certain 
professional groups have published recommendations (Table 2). 
Guidelines American Cancer Society* 





When to start Approximately 3 years after 
onset of vaginal intercourse, 
but no later than age 21 years 
Within 3 years of onset of 
sexual activity or age 21 years, 
whichever comes first
Approximately 3 years after 
onset of sexual intercourse,
 but no later than age 21 years 
Intervals 
Conventional Pap test Annually; every 2–3 years for 
women aged >30 years with 
three negative cytology tests¶ 
At least every 3 years Annually; every 2–3 years 
for women aged >30 years with
three negative cytology tests¶ 
If liquid-based cytology used Every 2 years; every 2–3 years 
for women aged >30 years with 
three negative cytology tests¶
Insufficient evidence Annually; every 2–3 years for 
women aged >30 years with 
three negative cytology tests¶ 
If human papillomavirus 
(HPV) testing used as an 
adjunct to cytology 
Every 3 years if HPV negative, 
cytology negative 
Insufficient evidence Every 3 years if HPV negative, 
cytology negative 
* Source: Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA 
Cancer J Clin 2002;52:342–62. 
† Source: U.S.Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Available at http://www.ahrq.gov. 
§ Source: ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists: cervical cytology screening. Obstet Gynecol 2003;102:417–27. 
¶ Certain exemptions apply (e.g., women who are immunocompromised, infected with human immunodeficiency virus, or have history of prenatal exposure 
to diethylstilbesterol in utero). See guidelines for details. 
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The American College of Obstetricians and Gynecologists 
(ACOG), the American Cancer Society (ACS), and the U.S. 
Preventive Services Task Force (USPSTF) guidelines state that 
all women should have a Pap test for cervical cancer screen­
ing within 3 years of beginning sexual activity or by age 21 
years, whichever occurs first (Table 2) (74,100,101). USPSTF 
recommends a conventional Pap test at least every 3 years, 
regardless of age. ACOG recommends annual screening of 
women aged <30 years; ACS recommends annual or biennial 
screening in this age group, depending on use of conventional 
or liquid-based cytology. According to these national organi­
zations, women aged >30 years with three normal consecu­
tive Pap tests should be screened every 2–3 years. 
ACS and ACOG also recommend use of the HC2 High 
Risk test as an adjunct to regular Pap screening of women 
aged >30 years. If both tests are negative, women should be 
rescreened no more frequently than every 3 years. In addi­
tion, ACOG and the American Society of Colposcopy and 
Cervical Pathology (ASCCP) recommend that HPV DNA 
testing be used to triage women with equivocal, ASC-US 
Pap test results (102). USPSTF concluded that evidence is 
insufficient to recommend for or against routine use of HPV 
tests (100). 
An estimated 82% of women in the United States have had 
a Pap test during the preceding 3 years (103). Pap test rates 
for all age and ethnic populations have increased during the 
preceding two decades. However, certain groups continue to 
have lower screening rates. These include women with less 
than a high school education (77%); foreign-born women, 
especially women who have been in the United States for <10 
years (61%); women without health insurance (62%); and 
certain racial/ethnic populations such as Hispanics (77%) and 
Asians (71%). Approximately half of women who had cervi­
cal cancer diagnosed in the United States had not had a Pap 






The licensed vaccine is a quadrivalent HPV vaccine 
(GARDASILTM, produced by Merck and Co, Inc.). The L1 
major capsid protein of HPV is the antigen used for HPV 
vaccination (105). Using recombinant DNA technology, the 
L1 protein is expressed in Saccharomyces cerevisiae (yeast), and 
the proteins self-assemble into conformationally intact, non­
infectious VLPs. Each 0.5-mL dose contains 20 µg HPV 6 
L1 protein, 40 µg HPV 11 L1 protein, 40 µg HPV 16 L1 
protein, and 20 µg HPV 18 L1 protein. VLPs are adsorbed 
on an aluminum-containing adjuvant. Each 0.5-mL dose con­
tains 225 µg amorphous aluminum hydroxyphosphate sul­
fate. The formulation also includes sodium chloride, 
L-histidine, polysorbate 80, sodium borate, and water for in­
jection. The quadrivalent HPV vaccine contains no thimero­
sal or antibiotics. 
The vaccine should be stored at 2°C–8°C (36°F–46°F) and 
not frozen. 
Dose and Administration 
Quadrivalent HPV vaccine is administered intramuscularly 
as three separate 0.5-mL doses. The second dose should be 
administered 2 months after the first dose and the third dose 
6 months after the first dose. The vaccine is available as a 
sterile suspension for injection in a single-dose vial or a 
prefilled syringe. 
Efficacy 
One clinical study evaluated efficacy of monovalent HPV 
16 vaccine, and three studies evaluated efficacy of quadriva­
lent HPV vaccine: a phase II study of a monovalent HPV 16 
vaccine (protocol 005) (106,107), a phase II study of quadriva­
lent HPV vaccine (protocol 007) (108–110), both among 
females aged 16–23 years, and two phase III studies of 
quadrivalent HPV vaccine (protocols 013 and 015) among 
females aged 16–23 and 16–26 years, respectively. All were 
randomized, double-blind, placebo-controlled studies. 
The studies used prespecified endpoints to evaluate the 
impact of the quadrivalent vaccine in preventing HPV-related 
infection and disease. Phase II studies were primarily proof­
of-concept studies that evaluated the efficacy of vaccine using 
a persistent infection endpoint. Phase III studies evaluated 
the efficacy of vaccine on clinical lesions. Predefined combi­
nations of phase II and III studies were used to improve the 
precision of the efficacy findings. Various endpoints were as­
sessed in the different studies, including vaccine type-related 
persistent HPV infection, CIN, VIN and VaIN, and genital 
warts.  The primary endpoint and the basis for licensure was 
the combined incidence of HPV 16- and 18-related CIN 2/3 
or AIS. These endpoints served as surrogate markers for cer­
vical cancer. Studies using an invasive cervical cancer end­
point were not feasible because the standard of care is to screen 
for and treat CIN 2/3 and AIS lesions to prevent invasive 
cervical cancer. Furthermore, the time from acquisition of 
infection to the development of cancer can exceed 20 years. 
The two phase III efficacy studies of quadrivalent HPV vac­
cine (protocols 013 and 015) were international studies, which 
included persons from North America, South America, Eu­
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points also are available from the phase II study (protocol when analyses were restricted to participants who received all 
007) (108,110) and of monovalent HPV-16 vaccine (protocol 3 doses of vaccine, had no protocol violations, and no evi­
005) (107). dence of infection with the relevant vaccine HPV type (se-
The quadrivalent HPV vaccine has a high efficacy for pre- ronegative and HPV PCR-negative through 1 month after 
vention of vaccine HPV type HPV 6-, 11-, 16-, and 18- dose 3) (Tables 3 and 4) (111). No evidence exists of protec­
related persistent infection, vaccine type-related CIN, CIN tion against disease caused by vaccine types for which partici­
2/3, and external genital lesions (genital warts, VIN and VaIN) pants were PCR positive at baseline. Participants infected with 
TABLE 3. Summary of quadrivalent human papillomavirus (HPV) vaccine efficacy studies in the per protocol populations* 
Quadrivalent 
vaccine Placebo 
Outcome and protocol No.† Cases No. Cases % Efficacy (95% CI§) 
HPV 16- or 18- related CIN 2/3 or AIS¶ 
Protocol 005** 755 0 750 12 100.0 (65.1–100.0) 
Protocol 007 231 0 230 1 100.0 (-3734.9–100.0) 
Protocol 013 2,200 0 2,222 19 100.0 (78.5–100.0) 
Protocol 015 5,301 0 5,258 21 100.0†† (80.9–100.0) 
Combined protocols§§ 8,487 0 8,460 53 100.0†† (92.9–100.0) 
HPV 6-, 11-, 16-, 18- related CIN 
(CIN 1, CIN 2/3) or AIS 
Protocol 007 235 0 233 3 100.0 (-137.8–100.0) 
Protocol 013 2,240 0 2,258 37 100.0†† (89.5–100.0) 
Protocol 015 5,383 4 5,370 43 90.7 (74.4–97.6) 
Combined protocols§§ 7,858 4 7,861 83 95.2 (87.2–98.7) 
HPV 6-, 11-, 16-, 18- related genital warts 
Protocol 007 235 0 233 3 100.0 (-139.5–100.0) 
Protocol 013 2,261 0 2,279 29 100.0 (86.4–100.0) 
Protocol 015 5,401 1 5,387 59 98.3 (90.2–100.0) 
Combined protocols§§ 7,897 1 7,899 91 98.9 (93.7–100.0) 
Source: Adapted from Food and Drug Administration. Product approval information—licensing action, package insert: GARDASIL (quadrivalent human 
papillomavirus types 6, 11, 16, and 18), Merck & Co. Whitehouse Station, NJ: Food and Drug Administration; 2006. Available at http://www.fda.gov/ 
cber/label/HPVmer060806LB.pdf. 
* Populations consisted of persons who received all three vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, 
and were naïve (polymerase chain reaction–negative and seronegative) to the relevant HPV type(s) (types 6, 11, 16, and 18) before dose 1 and 
through 1 month post dose 3 (month 7).  Median follow-up time for protocols 007, 013, and 015 was 1.9 years; median follow-up time for protocol 005 
was 3.9 years. 




¶ CIN: cervical intraepithelial neoplasis; AIS: adenocarcinoma in situ.
 
** Evaluated only the HPV 16 L1 VLP vaccine component of GARDASIL. 
†† P-values were computed for pre-specified primary hypothesis tests. All p-values were <0.001, supporting the following conclusions: efficacy against 
HPV 16/18-related CIN 2/3 is >0 (protocol 015); efficacy against HPV 16/18-related CIN 2/3 is >25% (combined protocols); and efficacy against HPV 
6/11/16/18-related CIN is >20% (protocol 013). 
§§ Analyses of the combined trials were prospectively planned and included the use of similar study entry criteria. 
Note: Point estimates and confidence intervals are adjusted for person-time of follow-up. 
TABLE 4. Efficacy of quadrivalent human papillomavirus (HPV) vaccine against HPV 16- or 18-related condyloma, VIN 1 or VaIN 
1* and VIN 2/3 or VaIN 2/3 in the per protocol populations† (protocols 007, 013, and 015) 
Vaccine Placebo Efficacy 
Endpoint No.§ Cases No. Cases % (95% CI¶) 
Condyloma, VIN 1 or VaIN 1 7,769 0 7,741 24 100.0 (83.4–100.0) 
VIN 2/3 or VaIN 2/3 7,769 0 7,741 10 100.0 (55.5–100.0) 
Source: Food and Drug Administration.Vaccines and Related Biological Products Advisory Committee, May 18, 2006: FDA GARDASIL briefing information. 
Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2006. Available at http://www.fda.gov/ohrms/dockets/ac/ 
06/slides/2006-4222s-index.htm. 
* VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia. 
† Includes all persons who were not general protocol violators, received all three vaccinations within acceptable day ranges, and were seronegative at day 
1 and polymerase chain reaction–negative day 1 through month 7 for the relevant HPV type. 
§Number of persons with at least one follow-up visit after month 7. 
¶ Confidence interval. 
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one or more vaccine HPV types before vaccination were pro­
tected against disease caused by the other vaccine HPV types. 
No evidence exists that the vaccine protects against disease 
caused by nonvaccine HPV types. 
Persistent HPV Infection 
Two phase II studies evaluated persistent infection, defined 
as a vaccine HPV type detected by PCR at two or more con­
secutive visits 4 months apart or at a single visit if it was the last 
visit of record. In the phase II quadrivalent vaccine study (pro­
tocol 007), 276 women received the 20/40/40/20 µg dose for­
mulation of vaccine, and 275 received a placebo. The efficacy 
for prevention of persistent HPV 6, 11, 16, or 18 infection or 
disease at the end of study (approximately 2.5 years after dose 
3) was 89.5% (95% confidence interval [CI] = 70.7%–97.3%). 
Of the vaccinated persons with persistent infection endpoints, 
three had HPV 16 detected at the last visit (without observed 
persistence), and one had persistent infection with HPV 18 
(detected at both 12 and 18 months) but not at months 24, 30, 
or 36 (108). In the phase II study of a monovalent HPV 16 
vaccine (protocol 005), the efficacy against persistent HPV 16 
infection was 100% at a midpoint analysis (106) and 94.3% 
(CI = 87.8%–97.7%) at the end of the study (107). All seven 
cases in the vaccine group had HPV 16 DNA detected on the 
person’s last study visit (without observed persistence). 
Cervical Disease 
Two phase III trials evaluated efficacy against cervical disease. 
Protocol 015 included 12,157 women aged 16–26 years. Par­
ticipants had a Pap test, cervicovaginal sampling for HPV DNA 
testing, and detailed genital inspection at day 1 and months 7, 
12, 24, 36, and 48, and were referred to colposcopy using a pro­
tocol specified algorithm based on Pap test results. The primary 
study endpoint was incidence of HPV 16- or 18-related CIN 2, 
CIN 3, AIS, or cervical cancer. In a per protocol analysis, the 
vaccine efficacy was 100% (CI = 80.9%–100%) for prevention 
of HPV 16 or 18 related CIN 2/3 or AIS (Table 3). 
Protocol 013 included 5,442 females aged 16–23 years. Par­
ticipants had a Pap test at day 1 and at months 7, 12, 18, 24, 
30, 36, and 48 and were referred to colposcopy according to 
protocol. In addition, participants had detailed genital in­
spection, with biopsy of abnormalities and cervicovaginal sam­
pling for HPV DNA sampling. The study had two primary 
efficacy endpoints: 1) external genital lesions related to HPV 
6, 11, 16, or 18, including genital warts, VIN, VaIN, vulvar 
cancer, or vaginal cancer; and 2) cervical endpoints related to 
HPV 6, 11, 16, or 18, including CIN, AIS, or cervical can­
cer. In a per protocol analysis, the vaccine efficacy was 100% 
(CI = 89.5%–100%) for prevention of any grade CIN re­
lated to vaccine types (Table 3). 
In a planned combined efficacy analysis, including data from 
four clinical studies (protocol 005, 007, 013, and 015), pro­
tection against HPV 16- or 18-related CIN 2/3 or AIS was 
100% (CI = 92.9%–100%) (111). In a planned combined analy­
sis, including data from three studies (protocol 007, 013, and 
015), protection against any CIN attributed to HPV 6, 11, 16, 
or 18, the efficacy was 95.2% (CI = 87.2%–98.7%). Four cases 
of CIN occurred in the vaccine group; all were CIN 1. 
External Genital Lesions 
Data from three studies (protocol 007, 013, and 015) pro­
vide data on efficacy against external genital lesions. In a com­
bined analysis, the efficacy of quadrivalent HPV vaccine 
against HPV 6-, 11-, 16-, or 18-related external genital warts 
was 98.9% (CI = 93.7%–100%) in a per protocol analysis 
(Table 3). Efficacy against HPV 16- or 18-related VIN 2/3 or 
VaIN 2/3 was 100% (CI = 55.5–100.0) (Table 4). 
Efficacy in Females with Current or Previous 
Vaccine HPV-Type Infection 
Because participants were enrolled into the clinical trials 
even if they were HPV DNA or antibody positive, evaluating 
efficacy in females infected with a vaccine HPV type at the 
time of vaccination was possible. Overall, 27% of the study 
population had evidence of previous exposure to or infection 
with a vaccine HPV type. Among these participants, 74% 
were positive to only one vaccine HPV type and did not have 
evidence of infection with the other three types. Among par­
ticipants positive to one or more vaccine HPV types, the vac­
cine had high efficacy for prevention of disease caused by the 
remaining vaccine HPV types (112). 
The vaccine’s impact on the course of infection present at 
the time of infection was evaluated using data from four clini­
cal studies (protocols 005, 007, 013, and 015). Three differ­
ent groups were analyzed on the basis of antibody and HPV 
DNA detection at the time of vaccination (Table 5). Among 
persons seropositive to the relevant HPV type but HPV DNA 
negative, efficacy against CIN 2/3 or AIS caused by that type 
was 100% (CI = -63.6%–100%). Among women who were 
HPV DNA positive but seronegative, efficacy was 31.2% 
(CI = -4.5–54.9). Among women who were both seropostive 
and HPV DNA positive, efficacy against CIN 2/3 caused by 
that type was -25.8% (CI = -76.4%–10.1%). Because of the 
small numbers and wide confidence intervals around efficacy 
estimates, limited conclusions can be drawn from these estimates. 
Efficacy in the Intent-to-Treat Population 
Analyses among all women who received at least 1 dose of 
vaccine and had any follow-up 1 month after the first dose, 
regardless of initial PCR or serology, provide information on 
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TABLE 5. Efficacy of quadrivalent human papillomavirus (HPV) vaccine against HPV 16- or 18-related CIN 2/3 or AIS* caused by 
the HPV type with which the participant was or had been infected at the time of vaccination (protocols 005, 007, 013, and 015) 
Quadrivalent 
HPV vaccine Placebo Efficacy 
Baseline characteristics No. Cases No. Cases % (95% CI†) 
HPV DNA negative, 853 0 910 4 100.0 (-63.6–100.0) 
HPV seropositive 
HPV DNA positive, 661 42 626 57 31.2 (-4.5–54.9) 
HPV seronegative 
HPV DNA positive, 473 79 499 69 -25.8 (-76.4–10.1) 
HPV seropositive 
Source: Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee. FDA GARDASIL briefing information. Rockville, 
MD: US Department of Health and Human Services, Food and Drug Administration; 2006. Available at http://www.fda.gov/ohrms/dockets/ac/06/slides/ 
2006-4222s-index.htm. 
* CIN: cervical intraepithelial neoplasia; AIS: adenocarcinoma in situ. 
†Confidence interval. 
efficacy that would be seen in the total study population. At 
baseline, 27% of clinical trial participants had evidence of 
previous or current infection with a vaccine type HPV. In a 
combined analysis of protocols 005, 007, 013, and 015, the 
efficacy for prevention of HPV 16- or 18-related CIN 2/3 or 
AIS was 39.0% (CI = 23.3%–51.7%). In a combined analy­
sis of protocols 007, 013 and 015, efficacy for prevention of 
any vaccine-type–related CIN was 46.4% (CI = 35.2%– 
55.7%), for prevention of vaccine-type–related VIN 2/3 and 
VaIN 2/3 was 69.1% (CI = 29.8%–87.9%), and for preven­
tion of vaccine- type–related genital warts was 68.5% (CI = 
57.5%–77.0%). The lower efficacy in these analyses compared 
with the per protocol population indicates that certain women 
were infected with vaccine types before vaccination. A 12.2% 
(CI = -3.2%–25.3%) reduction occurred in any CIN 2/3 in 
the vaccinated group compared with the placebo group at a 
median follow-up time of 1.9 years (111). 
Duration of Protection 
A subset of participants (n = 241) in the phase II quadriva­
lent HPV vaccine study (protocol 007) is being followed for 
60 months after dose one. In a combined analysis of all partici­
pants through year 3 and a subset through 60 months, the effi­
cacy against vaccine HPV type persistent infection or disease 
was 95.8% (CI = 83.8%–99.5%) and efficacy against vaccine­
type–related CIN or external genital lesions was 100% (CI = 
12.4%–100%) (110). 
Follow-up studies are planned by Merck and Co., Inc. to 
determine duration of protection among women enrolled in 
the phase III studies through 3 years after dose 3. Additional 
data on duration of protection will be available from follow-
up of approximately 5,500 women enrolled in one of the phase 
III quadrivalent HPV vaccine studies in the Nordic coun­
tries. These women will be followed for at least 14 years; sero­
logic testing will be conducted 5 and 10 years after vaccination; 
and Pap testing results will be linked to data from vaccine 
registries to monitor outcomes. 
Immunogenicity 
Immunogenicity in Persons Aged 9–26 Years 
The immunogenicity of the quadrivalent HPV vaccine has 
been measured by detection of IgG antibody to the HPV L1 
by a type-specific competitive Luminex-based immunoassay 
(cLIA) in the majority of the studies (24,25). This assay mea­
sures antibodies against neutralizing epitopes for each HPV 
type. The units (milliMerck units) are internally consistent 
but cannot be directly compared across HPV types or with 
results from other HPV antibody assays. The height of the 
antibody titers (geometric mean titers [GMTs]) for the dif­
ferent types cannot be directly compared. 
Data on immunogenicity are available from Phase II (109) 
and Phase III double-blind, randomized, placebo-controlled 
trials conducted among females aged 16–26 years and immu­
nogenicity studies conducted among males and females aged 
9–15 years (113). In all studies conducted to date, >99% of 
study participants had an antibody response to all four HPV 
types in the vaccine 1 month after completing the 3-dose se­
ries (109,113). High seropositivity rates were observed after 
vaccination regardless of sex, ethnicity, country of origin, 
smoking status, or body mass index. 
Vaccination produced antibody titers higher than those after 
natural infection. Among females aged 16–23 years, anti-HPV 
6, 11, 16, and 18 GMTs 1 month after the third dose of 
vaccine were higher than those observed in participants who 
were HPV seropositive and PCR negative at enrollment in 
the placebo group (109). 
Vaccination of females who were seropositive to a specific 
vaccine HPV type at enrollment resulted in higher antibody 
titers to that type, particularly after the first dose, compared 
with those seronegative at enrollment (109), suggesting a 
boosting of naturally acquired antibody by vaccination. In 
studies among females aged 16–26 years, the interval between 
the first and second dose of vaccine ranged from 6 to 12 weeks. 
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Variation in the interval did not diminish the GMTs post-vac­
cination. Likewise, little impact of intervals was observed be­
tween the second and third dose ranging from 12 to 23 weeks. 
A serologic correlative of immunity has not been identified 
and no known minimal titer determined to be protective. The 
high efficacy found in the clinical trials to date has precluded 
identification of a minimum protective antibody titer. Fur­
ther follow-up of vaccinated cohorts might allow determina­
tion of serologic correlates of immunity. 
Immunogenicity Bridge to Efficacy Among 
Females 
Immunogenicity studies provide data, allowing compari­
son of seropositivity and GMTs among females aged 9–15 
years with those among females aged 16–26 years who were 
in the efficacy studies (Table 6) (111). Seropositivity rates in 
all age groups were approximately 99% for HPV 6, 11, 16, 
and 18. Anti-HPV responses 1 month post dose 3 among 
females aged 9–15 years were noninferior to those aged 16– 
26 years. At month 18, anti-HPV GMTs in females aged 9– 
15 years remained two to three fold higher than those observed 
at the same time point in females aged 16–26 years in the 
vaccine efficacy trials. 
Duration of Antibody 
The longest follow-up to date is 60 months in the phase II 
trial of quadrivalent HPV vaccine (110). Antibody titers de­
cline over time after the third dose but plateau by 24 months. 
At 36 months, anti-HPV 16 GMT among vaccinees remained 
higher than those in participants in the placebo group who 
were seropositive at baseline, and anti-HPV 6, 11, and 18 
titers were similar to those seropositive in the placebo group 
(109). At 36 months, seropositivity rates were 94%, 96%, 
100%, and 76% to HPV 6, 11, 16, and 18, respectively. No 
evidence exists of waning efficacy among participants who 
become seronegative during follow-up (110). Data from a 
revaccination study in which vaccinated women were given a 
challenge dose 5 years after enrollment into the study dem­
onstrated an augmented rise in antibody titer consistent with 
immune memory (114). 
Concomitant Administration of HPV Vaccine 
with Other Vaccines 
GMTs after concomitant administration of quadrivalent 
HPV vaccine and hepatitis B vaccine at all 3 doses were 
noninferior to GMTs after administration at separate visits. 
Studies are planned to evaluate concomitant administration 
with meningococcal conjugate vaccine and with the 
adolescent/adult formulation of tetanus, diphtheria and 
acellular pertussis (Tdap) vaccine. 
Safety and Adverse Events 
The quadrivalent HPV vaccine was evaluated for injection-
site and systemic adverse events, new medical conditions re­
ported during the follow-up period, and safety during 
pregnancy and lactation. Safety data on quadrivalent HPV 
vaccine are available from seven clinical trials and include 
11,778 persons aged 9–26 years who received quadrivalent 
vaccine and 9,686 who received placebo. Detailed data were 
collected using vaccination report cards for 14 days following 
each injection of study vaccine on a subset of participants 
aged 9–23 years. The population with detailed safety data 
included 5,088 females who received quadrivalent HPV vac­
cine and 3,790 who received placebo (Tables 7–9) (111). 
Local Adverse Events 
In the study population with detailed safety data, a larger 
proportion of persons reported injection-site adverse events 
TABLE 6. Immunogenicity bridging between females aged 9–15 years in the immunogenicity studies to females aged 16–26 
years in the quadrivalent human papillomavirus (HPV) vaccine efficacy studies (per-protocol immunogenicity population*) 
Females aged 9–15 years in Females aged 16–26 years in 
immunogenicity studies efficacy studies
 GMT§  GMT 
Assay (cLIA†) No. (mMU/mL) (95% CI¶) No. (mMU/mL) (95% CI) 
Anti-HPV 6 915 928.7 (874.0–986.8) 2,631 542.6 (526.2–559.6) 
Anti-HPV 11 915 1,303.0 (1,223.1–1,388.0) 2,655 761.5 (735.3–788.6) 
Anti-HPV 16 913 4,909.2 (4,547.6–5,299.5) 2,570 2,293.9 (2,185.0–2,408.2) 
Anti-HPV 18 920 1,039.8 (954.9–1,120.4) 2,796 461.6 (444.0–480.0) 
Source: Food and Drug Administration. Product approval information—licensing action, package insert: GARDASIL (quadrivalent human papillomavirus 
types 6, 11, 16, and 18), Merck & Co. Whitehouse Station, NJ: Food and Drug Administration; 2006. Available at http://www.fda.gov/cber/label/ 
HPVmer013007LB.pdf. 
* Includes all persons who were not general protocol violators, received all three vaccinations within acceptable day ranges, were seronegative at day 1 and 
(for all persons except those aged <16 years in the immunogenicity studies who were not tested) polymerase chain reaction–negative day 1 through 
month 7 for the relevant HPV type(s), and had a month 7 serum sample collected within an acceptable day range. 
† Competitive luminex immunoassay. 
§ Geometric mean titer; mMU: milli-Merck units. 
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TABLE 7. Injection-site adverse events among female participants aged 9–23 years in the detailed safety data, days 1–5 after 
any vaccination with quadrivalent human papillomavirus (HPV) vaccine 
Aluminum-containing 
Quadrivalent HPV vaccine placebo Saline placebo 
Adverse event (% Occurrence) (% Occurrence) (% Occurrence) 
Pain 83.9 75.4 48.6 
Mild/Moderate 81.1 74.1 48.0 
Severe 2.8 1.3 0.6 
Swelling* 25.4 15.8 7.3 
Mild/Moderate 23.3 15.2 7.3 
Severe 2.0 0.6 0 
Erythema* 24.7 18.4 12.1 
Mild/Moderate 23.7 18.0 12.1 
Severe 0.9 0.4 0 
Source: Food and Drug Administration.  Product approval information—licensing action, package insert: GARDASIL (quadrivalent human papillomavirus 
types 6, 11, 16, and 18), Merck & Co. Whitehouse Station, NJ: Food and Drug Administration; 2006. Available at http://www.fda.gov/cber/label/ 
HPVmer060806LB.pdf. 
* Intensity of swelling and erythema was measured by size (inches): mild: 0 to <1; moderate: >1 to <2; and severe: >2. 
TABLE 8. Systemic clinical adverse events among female in the group that received quadrivalent HPV vaccine com­
participants aged 9–23 years in the population with detailed pared with aluminum-containing or saline placebo groups 
safety data, days 1–15 after vaccination with quadrivalent 
(Table 7). Pain was the most common injection site adverse human papillomavirus (HPV) vaccine 
Adverse event Quadrivalent event, reported by 83.9% of vaccinees, 75.4% of those who 
(1–15 days	 HPV vaccine Placebo received aluminum-containing placebo, and 48.6% of those 
postvaccination) (N = 5,088) (N = 3,790) 
who received saline placebo. Swelling and erythema were the 
Pyrexia	 13.0% 11.2% 
next most common reactions in the vaccine and placebo 
Nausea	 6.7% 6.6% 
groups. The majority of injection-site adverse experiences re-Nasopharyngitis	 6.4% 6.4% 
ported among recipients of quadrivalent HPV vaccine were Dizziness 4.0% 3.7%
 
Diarrhea 3.6% 3.5% mild to moderate in intensity; only 2.8%, 2.0%, and 0.9% of
 
Vomiting 2.4% 1.9% vaccinees reported severe pain, swelling, or erythema,
 




Systemic Adverse EventsToothache 1.5% 1.4% 
Upper respiratory tract infection 1.5% 1.5% Systemic clinical adverse events were reported by a similar 
Malaise 1.4% 1.2% proportion of vaccine and placebo recipients in the popula-
Arthralgia	 1.2% 0.9% tion with detailed safety data (Table 8). In both quadrivalent 
Insomnia	 1.2% 0.9% HPV vaccine and placebo groups, more persons reported a 
Nasal congestion	 1.1% 0.9% systemic clinical adverse experience in the 15 days after dose
Source: Food and Drug Administration. Product approval information— 
licensing action, package insert: GARDASIL (quadrivalent human 1 compared with after dose 2 and after dose 3. For the major­
papillomavirus types 6, 11, 16, and 18), Merck & Co.Whitehouse Station, ity of persons, the maximum intensity rating of systemic clini-
NJ: Food and Drug Administration; 2006.  Available at http://www.fda.gov/ 
cber/label/HPVmer060806LB.pdf.	 cal adverse events was mild or moderate. Overall, 4.0%–4.9% 
of females who received quadrivalent HPV vaccine reported 
TABLE 9. Percentage of females aged 9–23 years with fever in the population with detailed safety data who had fever, days 1– 
5 after any vaccination with quadrivalent human papillomavirus (HPV) vaccine 
Quadrivalent HPV vaccine Placebo 
(% Occurrence) (% Occurrence) 
Temperature (°F)* Post dose 1 Post dose 2 Post dose 3 Post dose 1 Post dose 2 Post dose 3 
>100° to <102° 3.7 4.1 4.4 3.1 3.8 3.6 
>102° 0.3 0.5 0.5 0.3 0.4 0.6 
Source: Food and Drug Administration. Product approval information—licensing action, package insert: GARDASIL (quadrivalent human papillomavirus 
types 6, 11, 16, and 18), Merck & Co. Whitehouse Station, NJ: Food and Drug Administration; 2006. Available at http://www.fda.gov/cber/label/ 
HPVmer060806LB.pdf. 
* Oral or oral equivalent temperature. 
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a temperature of >100°F (>38°C) after dose one, two, or three 
(Table 9). 
Serious Adverse Events in All Safety Studies 
Vaccine-related serious adverse events occurred in <0.1% 
of persons. The proportions of persons reporting a serious 
adverse event were similar in the vaccine and placebo groups, 
as were the types of serious adverse events reported. Seven 
persons had events that were determined to be possibly, prob­
ably, or definitely related to the vaccine or placebo. Five events 
occurred among quadrivalent HPV vaccine recipients and two 
among placebo recipients. The five in the quadrivalent HPV 
vaccine group included bronchospasm, gastroenteritis, head­
ache/hypertension, vaginal hemorrhage, and injection site 
pain/movement impairment. 
In the overall safety evaluation, 10 persons in the group 
that received quadrivalent HPV vaccine and seven persons in 
the placebo group died during the course of the trials. None 
of the deaths was considered to be vaccine related. Two deaths 
in the vaccine group and one death in the placebo group oc­
curred within 15 days following vaccination. Seven deaths 
were attributed to motor-vehicle accidents (four in vaccine 
group and three in placebo group), three were caused by in­
tentional overdose (nonstudy medications) or suicide (one in 
vaccine group and two in placebo group), two were attrib­
uted to pulmonary embolus or deep venous thrombosis (one 
each in vaccine and placebo group), two were attributed to 
sepsis, one case each attributed to cancer and arrhythmia (in 
vaccine group), and one case caused by asphyxia (placebo 
group). 
New Medical History 
Information was collected on new medical conditions that 
occurred in up to 4 years of follow-up. Overall, nine (0.08%) 
participants in the vaccine group and three (0.03%) partici­
pants in the placebo group had conditions potentially indica­
tive of autoimmune disorders, including various arthritis 
diagnoses (nine in vaccine group and two in placebo group) 
and systemic lupus erythematosis (none in vaccine group and 
one in placebo group) (111). No statistically significant dif­
ferences exist between vaccine and placebo recipients for the 
incidence of these conditions. 
Vaccination During Pregnancy 
The quadrivalent clinical trial protocols excluded women 
who were pregnant. Human beta gonadotropin testing was 
conducted before administration of each vaccine dose, and if 
women were found to be pregnant, vaccination was delayed 
until completion of pregnancy. Nevertheless, among clinical 
trial participants, 1,244 pregnancies occurred in the vaccine 
group and 1,272 occurred in the placebo group (Table 10) 
(111). Among those with known outcomes (996 and 1,018), 
the percentage with spontaneous loss was similar in both 
groups (25%). A total of 15 and 16 congenital abnormalities 
occurred in the vaccine and placebo groups, respectively, in­
cluding five in the vaccine group and none in the placebo 
group among infants born to women who received vaccine or 
placebo within 30 days of estimated onset of pregnancy. The 
five congenital abnormalities were determined by an expert 
panel to be unrelated (one pyloric stenosis with ankyloglos­
sia, one congenital hydronephrosis, one congenital megaco­
lon, one club foot, and one hip dysplasia). Rates of congenital 
abnormalities in the study were consistent with those in sur­
veillance registries. Quadrivalent HPV vaccine has been clas­
sified as Category B on the basis of animal studies in rats 
showing no evidence of impaired fertility or harm to the fetus. 
Vaccination During Lactation 
In the clinical trials, 995 women in the evaluated popula­
tion (500 and 495 persons in the group that received quadriva­
lent HPV vaccine or placebo, respectively) were breast feeding 
during the vaccination period. A total of 17 (3.4%) and nine 
(1.8%) infants of women who breastfed who received 
quadrivalent HPV vaccine or placebo, respectively, experi­
enced a serious adverse event. Of the 23 experiences among 
the 17 infants of women who received vaccine, 12 were respi­
ratory infections, five were gastroenteritis or diarrhea, and 
the remaining included various other single events. None was 
considered vaccine related. 
TABLE 10. Pregnancy outcomes in the quadrivalent human 
papillomavirus (HPV) vaccine phase III database 
Quadrivalent 
HPV vaccine Placebo 
Outcome No. (%) No. (%) 
Women with pregnancies 1,115 (10.7) 1,151 (12.6) 
No. of pregnancies 1,244 1,272 
Infants/fetuses 996 1,018 
with known outcomes 
Live births* 621 (62.3) 611 (60.0) 
Spontaneous miscarriage* 249 (25.0) 257 (25.2) 
Late fetal deaths* 11 (1.1) 8 (0.8) 
Congenital anomalies* 15 (1.5) 16 (1.6) 
Source: Food and Drug Administration. Vaccines and Related Biological 
Products Advisory Committee, May 18, 2006: FDA GARDASIL briefing 
information. Rockville, MD: US Department of Health and Human 
Services, Food and Drug Administration; 2006. Available at http:// 
www.fda.gov/ohrms/dockets/ac/06/slides/2006-4222s-index.htm. 
* Percentage of those with known outcomes. 
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Impact of Vaccination and Cost 
Effectiveness 
Economic Burden of HPV 
The prevention and treatment of anogenital warts and cer­
vical HPV-related disease imposes an estimated burden of $4 
billion or more (2004 dollars) in direct costs in the United 
States each year (70,71,115). Of this, approximately $200 
million is attributable to the management of genital warts; 
approximately $300–$400 million to invasive cervical can­
cer; and the remainder to routine cervical cancer screening, 
the follow-up of abnormal Pap tests, and pre-invasive cervi­
cal cancer (71,115). The estimated economic burden associ­
ated with HPV would be more substantial if the cost of other 
HPV-related diseases (e.g., vaginal and anal cancer and RRP) 
were included. 
Expected Impact of Vaccination 
Various different models have been developed to evaluate 
the impact of HPV vaccine (116). Markov models have sug­
gested that vaccination of an entire cohort of females aged 12 
years could reduce the lifetime risk for cervical cancer by 20%– 
66% (117,118) in that cohort, depending on the efficacy of 
the vaccine and the duration of vaccine protection. Models 
also project decreases in Pap test abnormalities and cervical 
cancer precursor lesions as a result of vaccination. For ex­
ample, incidence of low-grade Pap test abnormalities would 
decrease by 21% over the life of a vaccinated cohort of fe­
males aged 12 years (117). Models that incorporate HPV trans­
mission dynamics suggest an even greater potential impact of 
HPV vaccination on cervical cancer and cervical cancer pre­
cursors (119–121). Decreases in cervical cancer incidence and 
precursor lesions would occur more quickly with catch-up 
vaccination according to models that evaluated catch-up for 
females aged 12–24 years (121,122). 
Cost Effectiveness of HPV Vaccine 
Since 2003, four studies have estimated the potential cost 
effectiveness of HPV vaccination in the context of cervical 
cancer screening practices in the United States (117–119,121). 
Two of these studies applied Markov models to estimate the 
cost per quality-adjusted life year (QALY), focusing on the 
costs and impact of HPV vaccination for a given cohort, with­
out considering the effect of vaccination on HPV transmis­
sion in the population (herd immunity). The other studies 
applied dynamic transmission models to incorporate the ben­
efits of herd immunity in estimating the cost effectiveness of 
HPV vaccination. 
The two studies based on Markov models of the natural 
history of HPV infection examined the cost effectiveness of 
vaccinating females aged 12 years. One study assumed 100% 
vaccine coverage, 90% vaccine efficacy against HPV 16/18, 
lifetime duration of protection, and a cost of $377 per vac­
cine series (118). Under these assumptions, an estimated 58% 
reduction was achieved in the lifetime risk for cervical cancer 
for the vaccinated cohort at a cost of $24,300 (2002 dollars) 
per QALY compared with no vaccination. A second study 
assumed 70% vaccine coverage, 75% efficacy against all high-
risk HPV types, 10 years duration of protection plus 10 addi­
tional years of protection with a booster, and a cost of $300 per 
vaccine series plus $100 per booster (117). Under these assump­
tions, an estimated 20% reduction in cervical cancer incidence 
was achieved in the vaccinated cohort at a cost of $22,800 per 
QALY (2001 dollars) compared with no vaccination. 
The two cost effectiveness analyses based on dynamic trans­
mission models examined the cost effectiveness of vaccinat­
ing females. One study assumed vaccination at age 12 years 
with 70% vaccine coverage. The vaccine cost $300 per series 
plus $100 per booster and targeted HPV 16/18 with 90% 
efficacy and 10-year duration of protection plus 10 additional 
years with a booster (119). Under these assumptions, the life­
time risk for cervical cancer among vaccinated females would 
be reduced by 62% at a cost per QALY of $14,600 (2001 
dollars) compared with no vaccination. A second study as­
sumed vaccination at or before age 12 years with 70% vac­
cine coverage (121). The vaccine cost $360 per series and 
targeted HPV types 6, 11, 16, and 18, with 90% efficacy 
against infection and 100% efficacy against HPV-related dis­
eases attributable to these HPV types, with lifelong duration 
of protection. Under these assumptions, over the long term, a 
reduction of approximately 75% was achieved in the cervical 
cancer incidence rate attributable to HPV 16 and 18 at a cost 
of $3,000 per QALY in 2005 dollars compared with no vac­
cination. This model also suggested that a catch-up program 
for females aged 12–24 years would cost $4,700 per QALY 
compared with vaccination of females aged 12 years only. 
The cost per QALY gained by routine vaccination of fe­
males at age 12 years in the published studies ranged from 
$3,000 to $24,300. The results summarized are calculated 
using base-case scenarios, which vary across studies. In the 
sensitivity analyses, when base-case assumptions were modi­
fied, the estimated cost effectiveness ratios changed substan­
tially. For example, factors such as duration of vaccine-induced 
protection, duration of natural immunity, frequency of cervi­
cal cancer screening, vaccine coverage, and vaccine cost im­
pacted the estimated cost effectiveness of HPV vaccination 
(116–119,121,123). 
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Summary of Rationale
 




The availability of a quadrivalent HPV vaccine offers an 
opportunity to decrease the burden of HPV infection and its 
sequelae, including cervical cancer precursors, cervical can­
cer, other anogenital cancers, and genital warts in the United 
States. Quadrivalent HPV vaccine is licensed for use among 
females aged 9–26 years. In this age group, clinical trials indi­
cate that the vaccine is safe and immunogenic. Trials among 
females aged 16–26 years indicated the vaccine to be effective 
against HPV types 6-, 11-, 16-, and 18-related cervical, 
vaginal and vulvar cancer precursor and dysplastic lesions, 
and genital warts. HPV 16 and 18 are the cause of approxi­
mately 70% of cervical cancers; HPV 6 and 11 are the cause 
of approximately 90% of genital warts. Because HPV is sexu­
ally transmitted and often acquired soon after onset of sexual 
activity, vaccination should ideally occur before sexual debut. 
The recommended age for vaccination is 11–12 years; vaccine 
can be administered to females as young as age 9 years. At the 
beginning of a vaccination program, females aged >12 years 
will exist who did not have the opportunity to receive vaccine 
at age 11–12 years. Catch-up vaccination is recommended for 
females aged 13–26 years who have not yet been vaccinated. 
The recommendation for routine vaccination of females 
aged 11–12 years is based on several considerations, includ­
ing studies suggesting that quadrivalent HPV vaccine among 
adolescents will be safe and effective; high antibody titers 
achieved after vaccination at age 11–12 years; data on HPV 
epidemiology and age of sexual debut in the United States; 
and the high probability of HPV acquisition within several 
years of sexual debut. Ideally, HPV vaccine should be admin­
istered before sexual debut, and duration of protection should 
extend for many years, providing protection when exposure 
through sexual activity might occur. The vaccine has been 
demonstrated to provide protection for at least 5 years with­
out evidence of waning protection. Long-term follow-up stud­
ies are underway to determine duration of protection. The 
recommendation also considered cost effectiveness evaluations 
and the established young adolescent health-care visit at age 
11–12 years recommended by several professional organiza­
tions, when other vaccines are also recommended. 
Although routine vaccination is recommended at age 11– 
12 years, the majority of females aged 13–26 years also can 
benefit from vaccination. Females not yet sexually active can 
be expected to receive the full benefit of vaccination. Although 
sexually active females in this age group might have been in­
fected with one or more vaccine HPV types, type-specific 
prevalence studies in the United States suggest that a small 
percentage of sexually active females have been infected with 
all four of the HPV vaccine types. These data, available from 
North American females aged 16–24 years who participated 
in the quadrivalent vaccine trials, are from women who were 
more likely to have ever had sex than similar aged females in 
the general U.S. population. Among those sexually active fe­
males, the median number of lifetime sex partners (two) was 
similar in trial participants and females in the general U.S. 
population. The vaccine does not appear to protect against 
persistent infection, cervical cancer precursor lesions, or genital 
warts caused by an HPV type that females are infected with 
at the time of vaccination. However, females already infected 
with one or more vaccine HPV types before vaccination would 
be protected against disease caused by the other vaccine HPV 
types. Therefore, although overall vaccine effectiveness would 
be lower when administered to a population of females who 
are sexually active, and would decrease with older age and 
likelihood of HPV exposure with increasing number of sex 
partners, the majority of females in this age group will derive 
at least partial benefit from vaccination. 
Recommendations for Use 
of HPV Vaccine 
Recommendations for Routine Use and 
Catch-Up 
Routine Vaccination of Females Aged 11–12 
Years 
ACIP recommends routine vaccination of females aged 11– 
12 years with 3 doses of quadrivalent HPV vaccine. The vac­
cination series can be started as young as age 9 years. 
Catch-Up Vaccination of Females Aged 13–26 
Years 
Vaccination also is recommended for females aged 13–26 
years who have not been previously vaccinated or who have 
not completed the full series. Ideally, vaccine should be ad­
ministered before potential exposure to HPV through sexual 
contact; however, females who might have already been ex­
posed to HPV should be vaccinated. Sexually active females 
who have not been infected with any of the HPV vaccine 
types would receive full benefit from vaccination. Vaccina­
tion would provide less benefit to females if they have already 
been infected with one or more of the four vaccine HPV types. 
However, it is not possible for a clinician to assess the extent 
to which sexually active persons would benefit from vaccina­
tion, and the risk for HPV infection might continue as long 
as persons are sexually active. Pap testing and screening for 
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HPV DNA or HPV antibody are not needed before vaccina­
tion at any age. 
Dosage and Administration 
The vaccine should be shaken well before administration. 
The dose of quadrivalent HPV vaccine is 0.5 mL, adminis­
tered intramuscularly (IM), preferably in the deltoid muscle. 
Recommended Schedule 
Quadrivalent HPV vaccine is administered in a 3-dose 
schedule. The second and third doses should be administered 
2 and 6 months after the first dose. 
Minimum Dosing Intervals and Management 
of Persons Who Were Incorrectly Vaccinated 
The minimum interval between the first and second doses 
of vaccine is 4 weeks. The minimum recommended interval 
between the second and third doses of vaccine is 12 weeks. 
Inadequate doses of quadrivalent HPV vaccine or vaccine 
doses received after a shorter-than-recommended dosing in­
terval should be readministered. 
Interrupted Vaccine Schedules 
If the quadrivalent HPV vaccine schedule is interrupted, 
the vaccine series does not need to be restarted. If the series is 
interrupted after the first dose, the second dose should be 
administered as soon as possible, and the second and third 
doses should be separated by an interval of at least 12 weeks. 
If only the third dose is delayed, it should be administered as 
soon as possible. 
Simultaneous Administration with Other 
Vaccines 
Although no data exist on administration of quadrivalent 
HPV vaccine with vaccines other than hepatitis B vaccine, 
quadrivalent HPV vaccine is not a live vaccine and has no 
components that adversely impact safety or efficacy of other 
vaccinations. Quadrivalent HPV vaccine can be administered 
at the same visit as other age appropriate vaccines, such as the 
Tdap and quadrivalent meningococcal conjugate (MCV4) 
vaccines. Administering all indicated vaccines together at a 
single visit increases the likelihood that adolescents and young 
adults will receive each of the vaccines on schedule. Each vac­
cine should be administered using a separate syringe at a dif­
ferent anatomic site. 
Cervical Cancer Screening Among Vaccinated 
Females 
Cervical cancer screening recommendations have not 
changed for females who receive HPV vaccine (Table 2). HPV 
types in the vaccine are responsible for approximately 70% of 
cervical cancers; females who are vaccinated could subse­
quently be infected with a carcinogenic HPV type for which 
the quadrivalent vaccine does not provide protection. Fur­
thermore, those who were sexually active before vaccination 
could have been infected with a vaccine type HPV before 
vaccination. Health-care providers administering quadriva­
lent HPV vaccine should educate women about the impor­
tance of cervical cancer screening. 
Groups for Which Vaccine is Not 
Licensed 
Vaccination of Females Aged <9 Years and 
>26 Years 
Quadrivalent HPV vaccine is not licensed for use among 
females aged <9 years or those aged >26 years. Studies are 
ongoing among females aged >26 years. No studies are under 
way among children aged <9 years. 
Vaccination of Males 
Quadrivalent HPV vaccine is not licensed for use among 
males. Although data on immunogenicity and safety are avail­
able for males aged 9–15 years, no data exist on efficacy in 
males at any age. Efficacy studies in males are under way. 
Special Situations Among Females 
Aged 9–26 Years 
Equivocal or Abnormal Pap Test or Known 
HPV Infection 
Females who have an equivocal or abnormal Pap test could 
be infected with any of approximately 40 high-risk or low-
risk genital HPV types. Such females are unlikely to be in­
fected with all four HPV vaccine types, and they might not 
be infected with any HPV vaccine type. Vaccination would 
provide protection against infection with HPV vaccine types 
not already acquired. With increasing severity of Pap test find­
ings, the likelihood of infection with HPV 16 or 18 increases 
and the benefit of vaccination would decrease. Women should 
be advised that results from clinical trials do not indicate the 
vaccine will have any therapeutic effect on existing HPV in­
fection or cervical lesions. 
Females who have a positive HC2 High-Risk test conducted 
in conjunction with a Pap test could have infection with any 
of 13 high-risk types. This assay does not identify specific 
HPV types, and testing for specific HPV types is not con­
ducted routinely in clinical practice. Women with a positive 
HC2 High-Risk test might not have been infected with any 
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of the four HPV vaccine types. Vaccination would provide 
protection against infection with HPV vaccine types not al­
ready acquired. However, women should be advised that re­
sults from clinical trials do not indicate the vaccine will have 
any therapeutic effect on existing HPV infection or cervical 
lesions. 
Genital Warts 
A history of genital warts or clinically evident genital warts 
indicates infection with HPV, most often type 6 or 11. How­
ever, these females might not have infection with both HPV 
6 and 11 or infection with HPV 16 or 18. Vaccination would 
provide protection against infection with HPV vaccine types 
not already acquired. However, females should be advised that 
results from clinical trials do not indicate the vaccine will 
have any therapeutic effect on existing HPV infection or geni­
tal warts. 
Lactating Women 
Lactating women can receive HPV vaccine. 
Immunocompromised Persons 
Because quadrivalent HPV vaccine is a noninfectious vac­
cine, it can be administered to females who are immunosup­
pressed as a result of disease or medications. However, the 
immune response and vaccine efficacy might be less than that 
in persons who are immunocompetent. 
Vaccination During Pregnancy 
Quadrivalent HPV vaccine is not recommended for use in 
pregnancy. The vaccine has not been causally associated with 
adverse outcomes of pregnancy or adverse events in the devel­
oping fetus. However, data on vaccination during pregnancy 
are limited. Until additional information is available, initia­
tion of the vaccine series should be delayed until after comple­
tion of the pregnancy. If a woman is found to be pregnant 
after initiating the vaccination series, the remainder of the 3­
dose regimen should be delayed until after completion of the 
pregnancy. If a vaccine dose has been administered during 
pregnancy, no intervention is needed. A vaccine in pregnancy 
registry has been established; patients and health-care provid­
ers should report any exposure to quadrivalent HPV vaccine 
during pregnancy (telephone: 800-986-8999). 
Precautions and Contraindications 
Acute Illnesses 
Quadrivalent HPV vaccine can be administered to persons 
with minor acute illnesses (e.g., diarrhea or mild upper respi­
ratory tract infections with or without fever). Vaccination of 
persons with moderate or severe acute illnesses should be de­
ferred until after the patient improves (124). 
Hypersensitivity or Allergy to Vaccine 
Components 
Quadrivalent HPV vaccine is contraindicated for persons 
with a history of immediate hypersensitivity to yeast or to 
any vaccine component. Data from passive surveillance in 
Vaccine Adverse Event Reporting System (VAERS) indicates 
that recombinent yeast derived vaccines pose a minimal risk 
for anaphylaxic reactions in persons with a history of allergic 
reactions to Saccharomyces cerevisiae (baker’s yeast) (125). 
Preventing Syncope After Vaccination 
Syncope (i.e., vasovagal or vasodepressor reaction) can oc­
cur after vaccination, most commonly among adolescents and 
young adults (124). Among reports to VAERS for any vac­
cine that were coded as syncope during 1990–2004, a total of 
35% of these episodes were reported among persons aged 10– 
18 years. Through January 2007, the second most common 
report to VAERS following receipt of HPV vaccine was syn­
cope (CDC, unpublished data, 2007). Vaccine providers 
should consider observing patients for 15 minutes after they 
receive HPV vaccine. 




As with any newly licensed vaccine, surveillance for rare 
adverse events associated with administration of quadrivalent 
HPV vaccine is important for assessing its safety in wide­
spread use. All clinically significant adverse events should be 
reported to VAERS at http://vaers.hhs.gov, even if causal re­
lation to vaccination is not certain. VAERS reporting forms 
and information are available electronically at http:// 
www.vaers.hhs.gov or by telephone (800-822-7967). Web-
based reporting is available and providers are encouraged to 
report electronically at https://secure.vaers.org/ 
VaersDataEntryintro.htm to promote better timeliness and 
quality of safety data. 
Safety surveillance for adolescent quadrivalent HPV vac­
cine, Tdap, MCV4, and other vaccines is being conducted 
on an ongoing basis in cooperation with FDA. A vaccine in 
pregnancy registry has been established by Merck and Co., 
Inc.; patients and health-care providers should report any ex­
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Areas for Research and Program 
Activity Related to HPV Vaccine 
With licensure and introduction of quadrivalent HPV vac­
cine for females, monitoring impact of vaccination and vac­
cine safety will be needed. Research in several areas is ongoing, 
and research in other areas is needed. 
Duration of Protection from the Quadrivalent Vaccine: 
Long-term data on duration of antibody response and clini­
cal protection will be obtained through studies conducted in 
the Nordic countries through the Nordic cancer registries and 
through other studies in the United States (111). Follow up 
of vaccine trial participants aged 9–15 years will continue for 
up to 10 years after dose 3. This will include evaluation of 
antibody titers and, in participants who reach their 16th birth­
day, evaluation of vaccine effectiveness. 
Surveillance for HPV-Related Outcomes: Although it will 
take years to realize the impact of vaccination on cervical can­
cer, decreases in cervical cancer precursors and genital warts 
should be realized sooner. Studies are planned to monitor these 
lesions and other HPV-related outcomes in the United States. 
Virologic Surveillance: Prevalence and incidence of HPV 
types in the vaccine are expected to decrease as a result of 
vaccination. Studies are planned to monitor HPV types in 
various populations and specimens. 
Safety of Vaccination: Postlicensure studies to evaluate gen­
eral safety and pregnancy outcomes will be conducted by the 
manufacturer and independently by CDC. Monitoring will 
be accomplished through VAERS and CDC’s Vaccine Safety 
Datalink, which will include surveillance of cohorts of re­
cently vaccinated females and evaluation of outcomes of preg­
nancy among those pregnant at the time of vaccination. The 
manufacturer will be monitoring long-term safety as part of 
the Nordic Cancer Registry Program (111). 
Simultaneous Vaccination: Safety and immunogenicity 
studies of simultaneous administration of quadrivalent HPV 
vaccine with Tdap and MCV4 are ongoing. 
Efficacy of HPV Vaccine in Men: Studies are needed to 
define the efficacy of HPV vaccination in preventing genital 
warts and anogenital intraepithelial neoplasia in men. Stud­
ies of the effectiveness of HPV vaccination of men in pre­
venting transmission to both female and male sex partners 
are also needed. 
Cervical Cancer Screening: Recommendations for cervi­
cal cancer screening guidelines have not changed. Evaluation 
of the impact of HPV vaccination on cervical cancer screen­
ing provider practices and women’s screening behavior is 
needed as well as further economic analyses. 
Vaccine Delivery and Implementation: Administration 
of 3 doses of vaccine in adolescents will be challenging. Pro­
grammatic research is needed to determine optimal strategies 
to reach this age group. 
Vaccines for Children Program 
The Vaccines for Children (VFC) program supplies vac­
cines to all states, territories, and the District of Columbia 
for use by participating providers. These vaccines are to be 
administered to eligible children without cost to the patients 
or the provider. All routine childhood vaccines recommended 
by ACIP are available through this program. The program 
saves patients and providers out-of-pocket expenses for vac­
cine purchases and provides cost savings to states through 
CDC vaccine contracts. The program results in lower vac­
cine prices and ensures that all states pay the same contract 
prices. Detailed information about the VFC program is avail­
able at http://www.cdc.gov/nip/vfc/default.htm. 
Additional Information About HPV 
and HPV Vaccine 
Additional information about HPV and HPV vaccine is 
available from several sources, and new information will be 
available in the future. Updated information about HPV, cer­
vical cancer, and HPV vaccine is available at the following 
websites: http://www.cdc.gov/nip/vaccine/hpv; http:// 
www.cdc.gov/cancer; http://www.cdc.gov/std/hpv; http:// 
www.cancer.gov/cancertopics/hpv-vaccines; http://www. 
cancer.org; and http://www.ashastd.org/hpv. 
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Goals and Objectives 
This report provides recommendations on use of the licensed quadrivalent vaccine against human papillomavirus (HPV) for HPV types 6, 11, 16, and 18 
for the prevention of HPV-associated conditions such as cervical cancer, cervical cancer precursors, and anogenital warts. The recommendations were 
developed by CDC’s Advisory Committee on Immunization Practices. The goal of this report is to provide recommendations on the quadrivalent HPV 
vaccine for clinicians, public health officials, and others who are interested in preventing HPV-associated conditions in the United States. Upon completion 
of this educational activity, the reader should be able to 1) describe the epidemiology of HPV in the United States, 2) identify recommendations for HPV 
vaccination in the United States, and 3) and describe the characteristics of quadrivalent HPV vaccine. 
To receive continuing education credit, please answer all of the following questions. 
1.	 Which of the following are recommendations for the use of 
quadrivalent HPV vaccine? 
A.	 Females aged 11–12 years should routinely receive 3 doses of the 
quadrivalent HPV vaccine. 
B.	 Females as young as age 9 years can receive the quadrivalent HPV 
vaccine. 
C. Females aged 13–26 years who have not previously received the 
quadrivalent HPV vaccine are recommended to receive the 
quadrivalent HPV vaccine. 
D. All the above are recommendations for the use of HPV vaccine. 




3.	 The recommendation for HPV vaccination for females aged 11–12 
years is based on… 
A.	 studies suggesting that quadrivalent HPV vaccine among adolescents 
will be safe and effective. 
B.	 high antibody titers achieved after vaccination at this age. 
C. data on HPV epidemiology and age of sexual debut in the United 
States. 
D.	 all the above were considerations for HPV vaccination of females aged 
11–12 years. 
4.	 The most common vaccine-related adverse event in the clinical trials 
was… 
A.	 injection-site symptoms. 
B.	 fever. 
C. arrhythmia. 
D. generalized macular rash. 
5.	 Clinical trials currently provide data on duration of protection for 
how many months after vaccination? 
A.	 6 months. 
B.	 12 months. 
C. 60 months. 
D. 120 months. 
6.	 The per-protocol analysis of the efficacy trials indicated that the 
quadrivalent vaccine was how effective at preventing CIN 2/3 and 





7.	 Vaccinating females aged 9–26 years after sexual debut is 
recommended because few young women have been infected with all 
four HPV types contained in the vaccine and they would still get 
protection from those types they have not acquired. 
A.	 True. 
B.	 False. 
8.	 HPV vaccine is recommended for pregnant women. 
A.	 True. 
B.	 False. 
9.	 What vaccine(s) can be administered at the same visit as the 
quadrivalent HPV vaccine? 
A.	 Hepatitis B vaccine. 
B.	 Meningococcal conjugate vaccine. 
C. Tetanus, reduced diphtheria toxoid and acellular pertussis (Tdap) 
vaccine. 
D.	 All the above vaccines can be administered at the same visit as HPV 
vaccine. 
10. Which of the following best describe the epidemiology of HPV in the 
United States? 
A.	 Approximately six million new infections occur each year. 
B.	 The prevalence of infection peaks among young adults then declines 
with increasing age. 
C. HPV infection appears to be common among both females and males. 
D.	 All the above are correct about the epidemiology of HPV in the United 
States. 
11. Which of the following best describes HPV vaccine? 
A.	 Live-attenuated virus. 
B.	 Live-recombinant virus. 
C. Subunit. 
D. Toxoid. 
12. Women who receive HPV vaccine no longer need periodic Pap tests 
for cervical cancer screening. 
A.	 True. 
B.	 False. 
13. What two HPV types cause the majority of genital warts and recurrent 
respiratory papillomatosis? 
A.	 HPV 6 and HPV 11. 
B.	 HPV 16 and HPV 18. 
C. HPV 11 and HPV 16. 
D. HPV 31 and HPV 45. 
14. What best describes your professional activities? 
A.	 Physician. 
B.	 Nurse. 
C. Health educator. 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































15. I plan to use these recommendations as the basis for … (Indicate all 
that apply.) 
A.	 health education materials. 
B.	 insurance reimbursement policies. 
C.	 local practice guidelines. 
D. public policy. 
E.	 other. 
16. Overall, the length of the journal report was … 
A.	 much too long. 
B.	 a little too long. 
C.	 just right. 
D. a little too short. 
E.	 much too short. 
17. After reading this report, I am confident I can describe the 
epidemiology of HPV in the United States. 




E.	 Strongly disagree. 
18. After 	reading this report, I am confident I can identify 
recommendations for HPV vaccination in the United States. 




E.	 Strongly disagree. 
19. After reading this report, I am	 confident I can describe the 
characteristics of quadrivalent HPV vaccine. 




E.	 Strongly disagree. 
20. The learning outcomes (objectives) were relevant to the goals of this 
report. 




E.	 Strongly disagree. 
21. The instructional strategies used in this report (text, tables, and 
figures) helped me learn the material. 




E.	 Strongly disagree. 
22. The content was appropriate given the stated objectives of the report. 




E.	 Strongly disagree. 
(Continued on pg CE-4) 
Vol. 56 / No. RR-2 Recommendations and Reports	 CE-3 
Detach or photocopy. 
 
CE-4	 MMWR March 23, 2007 
23. The content expert(s) demonstrated expertise in the subject matter. 




E.	 Strongly disagree. 
24. Overall, the quality of the journal report was excellent. 




E.	 Strongly disagree. 
25. The recommendations will improve the quality of my practice. 




E.	 Strongly disagree. 
26. The availability of continuing education credit influenced my decision 
to read this report. 




E.	 Strongly disagree. 
27. The MMWR format was conductive to learning this content. 




E.	 Strongly disagree. 
28. Do you feel this course was commercially biased? 	 (Indicate yes or no; 
if yes, please explain in the space provided below.) 
A.	 Yes. 
B.	 No. 
29. How did you learn about the continuing education activity? 
A.	 Internet. 
B.	 Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal). 
C. Coworker/supervisor. 
D. Conference presentation. 
E.	 MMWR subscription. 
F.	 Other. 
Correct answers for questions 1–13. 
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